Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series

Abstract

Neutralizing monoclonal antibodies (mAbs) for pre- and post-exposure prophylaxis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) are largely used to prevent the progression of the disease by blocking viral attachment, host cell entry, and infectivity. Sotrovimab, like other available mAbs, has been developed against the receptor binding Domain of the Spike (S) glycoprotein of the virus. Nevertheless, the latest Omicron variant has shown marked mutations within the S gene, thus opening the question of the efficacy of these neutralizing molecules towards this novel variant. In the present observational study, we describe the effects of Sotrovimab in the treatment of 15 fully vaccinated patients, infected by SARS-CoV-2 Omicron sub-variants, who were selected on the basis of factors widely considered to affect a worse prognosis: immune suppression (n = 12) and/or chronic kidney disease (n = 5) with evidence of interstitial pneumonia in nine patients. The effectiveness of Sotrovimab in the treatment of severe cases of COVID-19 was demonstrated by the regression of symptoms (mean 5.7 days), no need of hospitalisation, improvement of general health conditions and viral clearance within 30 days in all patients. In conclusion, although loss or reduction of mAbs neutralizing activity against the Omicron variant have been described, Sotrovimab has clinically proven to be a safe and useful treatment for patients with high risk of progression to severe COVID-19 infected by Omicron sub-variants.

Pregnant Women’s Performance toward the COVID-19 Pandemic in El-Minia City

“…Fisher test was used **statistically significance differences at < 0.01 *statistically significant differences at < 0.05 NS= Not statistically Table (11): presents that there were no statistically significant differences between the total attitude, age, and occupation but there were statistically significant differences between the total attitude, education and economic status which P-value < 0.001. Chi test was used between qualitative variable **statistically significance differences at < 0.01 NS= Not statistically Table (12): presents that there were no statistically significant differences between the total precaution practices levels and occupation but there were statistically significant differences between the total precaution practices levels, age, and education and economic status which P-value < 0.001. Pearson correlation test was used **.…”

Early COVID‐19 treatment with Sotrovimab in high‐risk Beta‐thalassemia: Real‐life case‐series, state of the art and new perspectives

“…We showed the impact of mAb on the time duration of SARS-CoV-2 swab positivity, with a median of three days in the group treated (3,4), versus a median of 16 days (8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22) in the other group (51 patients) not treated. None of the three patients experienced adverse reactions, with good clinical outcomes, and hospitalization was not needed.…”

“…Larger studies are warranted to confirm its utility and benefit, in the evolving emergence of SARS-CoV-2 variants and subvariants. 17 We encourage finally the use of MASS and CAST scores to identify and stratify patients based on a prioritization strategy, reducing COVID-19-related admissions and decompressing an already overwhelmed hospital system. Furthermore, real-life studies such as this, herein, reported are important beyond registration studies, including a frail population such as thalassaemic patients who are not included in original clinical trials.…”